BPG is committed to discovery and dissemination of knowledge
Home / Archive / Volume 25, Issue 7
  • This Article
Peer-Review Report of This Article
CrossCheck and Google Search of This Article
Academic Rules and Norms of This Article
Citation of this article
Corresponding Author of This Article
Research Domain of This Article
Article-Type of This Article
Open-Access Policy of This Article
Times Cited Counts in Google of This Article
Journal Information of This Article
Publication Name
World Journal of Gastroenterology
ISSN
1007-9327
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews
©The Author(s) 2019.
World J Gastroenterol. Feb 21, 2019; 25(7): 789-807
Published online Feb 21, 2019. doi: 10.3748/wjg.v25.i7.789
Table 5 Results of the CERESTIAL trial[45]
Cabozantinib (n = 470)Placebo (n = 237)HR, P-value
OS (M, 95%CI)10.2 (9.1-12.0)8.0 (6.8-9.4)HR 0.76 (95%CI 0.63-0.92) P = 0.0049
PFS (M, 95%CI)5.2 (4.0-5.5)1.9 (1.9-1.9)HR 0.44 (95%CI 0.36-0.52) P < 0.0001
Objective response (investigator assessed, RECIST 1.1)
CR (%)00
PR (%)40.4
SD (%)6033
PD (%)2155
NE (%)1511
ORR (%, 95CI)4 (2.3-6.0)0.4 (0.0-2.3)P = 0.0086
DCR (%)6433.4
OS: Overall survival; PFS: Progression-free survival; TTP: Time to progression; CR: Complete response; PR: Partial response; SD: Stable disease; PD: Progressive disease; NE: Not evaluable; ORR: Objective response rate; DCR: Disease control rate.
Full Size Table
Write to the Help Desk
All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.